Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: Their differences and similarities to Western countries

Taku Kobayashi, Tadakazu Hisamatsu, Yasuo Suzuki, Haruhiko Ogata, Akira Andoh, Toshimitsu Araki, Ryota Hokari, Hideki Iijima, Hiroki Ikeuchi, Yoh Ishiguro, Shingo Kato, Reiko Kunisaki, Takayuki Matsumoto, Satoshi Motoya, Masakazu Nagahori, Shiro Nakamura, Hiroshi Nakase, Tomoyuki Tsujikawa, Makoto Sasaki, Kaoru YokoyamaNaoki Yoshimura, Kenji Watanabe, Miiko Katafuchi, Mamoru Watanabe, Toshifumi Hibi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.

Original languageEnglish
Pages (from-to)168-177
Number of pages10
JournalIntestinal Research
Volume16
Issue number2
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Disease Management
Inflammatory Bowel Diseases
Japan
Ulcerative Colitis
Crohn Disease
Molecular Epidemiology
Colectomy
Expert Testimony
Disease Progression
Gastrointestinal Tract
Colorectal Neoplasms
Hospitalization
Chronic Disease

Keywords

  • Colitis, ulcerative
  • Colorectal neoplasms
  • Consensus
  • Crohn disease
  • Prognosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan : Their differences and similarities to Western countries. / Kobayashi, Taku; Hisamatsu, Tadakazu; Suzuki, Yasuo; Ogata, Haruhiko; Andoh, Akira; Araki, Toshimitsu; Hokari, Ryota; Iijima, Hideki; Ikeuchi, Hiroki; Ishiguro, Yoh; Kato, Shingo; Kunisaki, Reiko; Matsumoto, Takayuki; Motoya, Satoshi; Nagahori, Masakazu; Nakamura, Shiro; Nakase, Hiroshi; Tsujikawa, Tomoyuki; Sasaki, Makoto; Yokoyama, Kaoru; Yoshimura, Naoki; Watanabe, Kenji; Katafuchi, Miiko; Watanabe, Mamoru; Hibi, Toshifumi.

In: Intestinal Research, Vol. 16, No. 2, 01.01.2018, p. 168-177.

Research output: Contribution to journalArticle

Kobayashi, T, Hisamatsu, T, Suzuki, Y, Ogata, H, Andoh, A, Araki, T, Hokari, R, Iijima, H, Ikeuchi, H, Ishiguro, Y, Kato, S, Kunisaki, R, Matsumoto, T, Motoya, S, Nagahori, M, Nakamura, S, Nakase, H, Tsujikawa, T, Sasaki, M, Yokoyama, K, Yoshimura, N, Watanabe, K, Katafuchi, M, Watanabe, M & Hibi, T 2018, 'Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: Their differences and similarities to Western countries', Intestinal Research, vol. 16, no. 2, pp. 168-177. https://doi.org/10.5217/ir.2018.16.2.168
Kobayashi, Taku ; Hisamatsu, Tadakazu ; Suzuki, Yasuo ; Ogata, Haruhiko ; Andoh, Akira ; Araki, Toshimitsu ; Hokari, Ryota ; Iijima, Hideki ; Ikeuchi, Hiroki ; Ishiguro, Yoh ; Kato, Shingo ; Kunisaki, Reiko ; Matsumoto, Takayuki ; Motoya, Satoshi ; Nagahori, Masakazu ; Nakamura, Shiro ; Nakase, Hiroshi ; Tsujikawa, Tomoyuki ; Sasaki, Makoto ; Yokoyama, Kaoru ; Yoshimura, Naoki ; Watanabe, Kenji ; Katafuchi, Miiko ; Watanabe, Mamoru ; Hibi, Toshifumi. / Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan : Their differences and similarities to Western countries. In: Intestinal Research. 2018 ; Vol. 16, No. 2. pp. 168-177.
@article{5aa355ed191d4ec7a468c61d5f177c8f,
title = "Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: Their differences and similarities to Western countries",
abstract = "Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.",
keywords = "Colitis, ulcerative, Colorectal neoplasms, Consensus, Crohn disease, Prognosis",
author = "Taku Kobayashi and Tadakazu Hisamatsu and Yasuo Suzuki and Haruhiko Ogata and Akira Andoh and Toshimitsu Araki and Ryota Hokari and Hideki Iijima and Hiroki Ikeuchi and Yoh Ishiguro and Shingo Kato and Reiko Kunisaki and Takayuki Matsumoto and Satoshi Motoya and Masakazu Nagahori and Shiro Nakamura and Hiroshi Nakase and Tomoyuki Tsujikawa and Makoto Sasaki and Kaoru Yokoyama and Naoki Yoshimura and Kenji Watanabe and Miiko Katafuchi and Mamoru Watanabe and Toshifumi Hibi",
year = "2018",
month = "1",
day = "1",
doi = "10.5217/ir.2018.16.2.168",
language = "English",
volume = "16",
pages = "168--177",
journal = "Intestinal Research",
issn = "1598-9100",
publisher = "Korean Association for the Study of Intestinal Diseases",
number = "2",

}

TY - JOUR

T1 - Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan

T2 - Their differences and similarities to Western countries

AU - Kobayashi, Taku

AU - Hisamatsu, Tadakazu

AU - Suzuki, Yasuo

AU - Ogata, Haruhiko

AU - Andoh, Akira

AU - Araki, Toshimitsu

AU - Hokari, Ryota

AU - Iijima, Hideki

AU - Ikeuchi, Hiroki

AU - Ishiguro, Yoh

AU - Kato, Shingo

AU - Kunisaki, Reiko

AU - Matsumoto, Takayuki

AU - Motoya, Satoshi

AU - Nagahori, Masakazu

AU - Nakamura, Shiro

AU - Nakase, Hiroshi

AU - Tsujikawa, Tomoyuki

AU - Sasaki, Makoto

AU - Yokoyama, Kaoru

AU - Yoshimura, Naoki

AU - Watanabe, Kenji

AU - Katafuchi, Miiko

AU - Watanabe, Mamoru

AU - Hibi, Toshifumi

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.

AB - Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.

KW - Colitis, ulcerative

KW - Colorectal neoplasms

KW - Consensus

KW - Crohn disease

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85047012620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047012620&partnerID=8YFLogxK

U2 - 10.5217/ir.2018.16.2.168

DO - 10.5217/ir.2018.16.2.168

M3 - Article

AN - SCOPUS:85047012620

VL - 16

SP - 168

EP - 177

JO - Intestinal Research

JF - Intestinal Research

SN - 1598-9100

IS - 2

ER -